Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure

New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Source Type: research

Related Links:

Publication date: Available online 20 July 2018Source: Revista Española de Cardiología (English Edition)Author(s): Aitor Uribarri, Manuel Barreiro, Ignacio Cruz-González, Pedro L. Sánchez
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
Authors: von Lueder TG, Agewall S PMID: 30023084 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Publication date: August 2018Source: American Journal of Kidney Diseases, Volume 72, Issue 2Author(s): Andrew A. HouseHeart failure and chronic kidney disease have increasing incidence and prevalence owing in part to the aging population and increasing rates of hypertension, diabetes, and other cardiovascular and kidney disease risk factors. The presence of one condition also has a strong influence on the other, leading to greater risks for hospitalization, morbidity, and death, as well as very high health care costs. Despite the frequent coexistence of heart failure and chronic kidney disease, many of the pivotal randomiz...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
ConclusionsAdjusted for demographic and clinical characteristics, the risk for developing de novo post–kidney transplantation heart failure has declined significantly between 1998 and 2010, with no apparent change in subsequent mortality.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
ConclusionsKidney tubular damage is an independent risk factor for CVD and death among elders. Future studies should investigate mechanisms by which kidney tubular damage may adversely affect cardiovascular risk.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
AbstractPatiromer (Veltassa®) for oral suspension is a non-absorbed, sodium-free potassium binding polymer that exchanges calcium for potassium in the gastrointestinal (GI) tract, thereby increasing faecal potassium excretion and reducing serum potassium levels. Patiromer was approved in the USA in 2015 and is now approved in several other countries, including those of the EU, for the treatment of hyperkalaemia in adults. In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with chronic kidney disease (CKD) and/or diabetic nephropathy with or without heart fai...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 20 July 2018Source: American Heart JournalAuthor(s): Robert J. Mentz, Christopher M. O'Connor, Bradi B. Granger, Hongqiu Yang, Chetan B. Patel, Karen E. Steinhauser, Mona Fiuzat, Kimberly S. Johnson, Kevin J. Anstrom, Gwen C. Dodson, Donald H. Taylor, Daniel B. Mark, James A. Tulsky, Joseph G. Rogers
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 20 July 2018Source: American Heart JournalAuthor(s): Nuccia Morici, Fabrizio Oliva, Silvia Ajello, Miriam Stucchi, Alice Sacco, Manlio Gianni Cipriani, Michele De Bonis, Andrea Garascia, Maria Pia Gagliardone, Giulio Melisurgo, Claudio Francesco Russo, Carlo La Vecchia, Maria Frigerio, Federico PappalardoManagement of acute decompensated heart failure (ADHF) patients presenting with cardiogenic shock (CS) is not straightforward, as few data are available from clinical trials. Stabilization before left ventricle assist device (LVAD) or heart transplantation (HTx) is strongly advocated, as ...
Source: American Heart Journal - Category: Cardiology Source Type: research
In conclusion, the data suggest that AMPK improved cardiac function during the development of chronic heart failure by attenuating autophagy, potentially via mTORC2 activation and the downstream effects. PMID: 30021848 [PubMed - in process]
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research
Publication date: Available online 19 July 2018Source: Mechanisms of Ageing and DevelopmentAuthor(s): Paweł Smykiewicz, Agnieszka Segiet, Michelle Keag, Tymoteusz ŻeraAbstractCardiovascular health deteriorates with age, and age is one of the strongest risk factors for cardiovascular complications including myocardial infarction, heart failure, cardiac arrhythmias, and death related to heart diseases. In this review, we show that expression of proinflammatory cytokines (PICs) increases throughout the human lifespan, and this increase is correlated with cardiovascular health, morbidity, and mortality. We argue that increas...
Source: Mechanisms of Ageing and Development - Category: Geriatrics Source Type: research
More News: Cardiology | Heart | Heart Failure | Internal Medicine